Loading...
OTCM
CSBTF
Market cap1.05bUSD
Jul 08, Last price  
25.57USD
1D
6.23%
1Q
-7.99%
IPO
-37.64%
Name

Kuros Biosciences AG

Chart & Performance

D1W1MN
OTCM:CSBTF chart
P/E
383.93
P/S
6.71
EPS
0.05
Div Yield, %
—
Shrs. gr., 5y
11.22%
Rev. gr., 5y
97.48%
Revenues
121m
+60.54%
724,00035,882,00019,723,0009,108,00022,349,0001,571,0001,100,0001,000,0001,000,0006,355,0001,061,000534,000715,0002,561,0004,039,00013,815,00017,986,00033,564,00075,555,000121,299,159
Net income
2m
P
-34,552,000-6,875,000-26,009,000-24,826,000-1,454,000-18,779,000-9,216,000-30,826,000-34,026,0006,227,000-19,744,000-16,484,000-11,693,000-11,252,000-11,520,000-7,541,000-14,595,000-13,727,000-3,716,0002,118,570
CFO
-378k
L
-28,674,000-4,398,000-27,895,000-15,248,000-4,685,000-8,807,000-11,537,000-19,170,000-23,758,000-2,514,000-8,893,000-10,678,000-12,838,000-10,849,000-9,239,000-5,453,000-7,348,000-8,844,0003,140,000-377,871

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Kuros Biosciences AG, a biopharmaceutical firm headquartered in Schlieren, Switzerland, specializes in both bringing to market and advancing therapeutic solutions for tissue repair and bone regeneration. Its global reach extends across the United States, the European Union, and other international markets, with operations strategically divided into Medical Devices, Pharmaceuticals, and a Legacy Portfolio. The company's innovative product lineup includes several key orthobiologics. Their MagnetOs Granules and MagnetOs Putty are already available in the EU and US, serving applications in orthopedics, spinal procedures, and dentistry. Additionally, their fibrin/PTH orthobiologics portfolio features KUR-111, which has successfully concluded Phase 2b clinical trials for treating tibial plateau fractures, and KUR-113, which completed Phase 2b trials for tibial shaft fractures and is currently in Phase II development for spinal interbody fusion. Beyond bone healing, Kuros Biosciences provides advanced sealant solutions, such as Neuroseal, a synthetic tissue sealant approved in the EU and US for preventing cerebrospinal fluid leakage after cranial or spinal surgeries. The company also fosters external partnerships, notably collaborating with Checkmate Pharmaceuticals LLC on the development of CYT003, an oncology treatment.
URL
http://www.kuros.ch/
IPO date
Oct 29, 2002
Employees
73
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT